Interleukin-4 (IL-4): A Key Determinant of Immune Response Types

Interleukin-4 (IL-4) is a cytokine with defining functions in the immune system, primarily driving type II helper T cell (Th2) immune responses. Unlike IL-2, which promotes cellular immunity, or IL-3, which regulates hematopoiesis, IL-4's core functions lie in promoting humoral immunity, regulating B cell antibody class switching, and playing central roles in allergic reactions, anti-parasitic immunity, and tissue repair. By binding to different types of receptors, it precisely modulates the direction of immune responses.

I. Overview of IL-4: Sources, Structure, and Receptor Systems

IL-4 is primarily produced by activated CD4⁺ T cells (especially differentiated Th2 cells). Additionally, basophils, mast cells, eosinophils, and certain type 2 innate lymphoid cells (ILC2s) are significant sources. It is a glycoprotein with a molecular weight of approximately 15-20 kDa.

The biological functions of IL-4 are mediated by its specific receptor (IL-4R). The IL-4R system consists of two main types, determining the cell-type specificity of its actions:

Type I IL-4 receptor: Composed of the IL-4Rα chain (CD124) and the common γ chain (γc, CD132). Primarily expressed on lymphocytes (e.g., T and B cells) and myeloid cells. IL-4 binding to this receptor is key to initiating Th2 differentiation and inducing B cell antibody class switching.

Type II IL-4 receptor: Composed of the IL-4Rα chain and the IL-13Rα1 chain. Mainly expressed on non-hematopoietic cells, such as epithelial cells, fibroblasts, endothelial cells, and some myeloid cells (e.g., macrophages). This receptor can also be activated by IL-13, explaining the extensive functional overlap between IL-4 and IL-13 in regulating mucus secretion, fibrosis, and other processes.

II. Core Mechanisms: Driving Th2 Immunity and Antibody Switching

IL-4 is one of the "directors" determining the type of adaptive immune response, with its core mechanisms reflected in its profound impact on immune cell differentiation and function.

1. Inducing Th2 Cell Differentiation and Expansion

Initiating Th2 polarization: During the early activation of naive CD4⁺ T cells, IL-4 in the local microenvironment (produced in small amounts by activated T cells themselves or provided by basophils or ILC2s) activates STAT6, upregulating the expression of the key transcription factor GATA3. GATA3 establishes the Th2 genetic program and suppresses Th1 differentiation.

Autocrine amplification loop: Differentiated Th2 cells produce large amounts of IL-4, further promoting their own clonal expansion and stabilizing the Th2 phenotype, forming a positive feedback loop that consolidates type II immune responses.

2. Regulating B Cell Function and Antibody Production

Inducing antibody class switching: This is one of IL-4's most classic functions. It induces activated B cells to undergo immunoglobulin heavy chain class switching, shifting from producing IgM/IgG to producing IgE and certain IgG subtypes (e.g., IgG1 in mice, IgG4 in humans). IgE is the key antibody mediating type I hypersensitivity reactions.

Promoting B cell proliferation and survival: As a B cell growth factor, IL-4 synergizes with B cell receptor (BCR) signaling to promote B cell proliferation, differentiation into plasma cells, and enhances their antigen-presenting capacity.

3. Regulating Macrophage Polarization

Inducing alternative activation (M2 polarization): IL-4 (and IL-13) are the primary drivers of macrophage polarization toward the M2 phenotype. M2 macrophages highly express mannose receptor (CD206), arginase-1, and others, functionally inclined toward tissue repair, fibrosis, anti-parasitic immunity, and possessing anti-inflammatory properties.

4. Enhancing Other Effector Cell Functions

Activating mast cells and eosinophils: IL-4 promotes the proliferation, survival, chemotaxis, and effector functions of these cells, amplifying inflammatory effects in allergies and anti-parasitic immunity.

III. Downstream Signaling Pathways: Core Transcriptional Regulation

Upon binding to its receptor, IL-4 primarily activates the following core signaling pathways:

JAK-STAT pathway (core pathway):

STAT6 activation: After IL-4 binds to type I or type II receptors, it recruits and activates JAK3 (coupled to the γc chain) or JAK2/Tyk2 (coupled to the IL-13Rα1 chain), respectively, while also activating JAK1 (coupled to the IL-4Rα chain). These JAK kinases phosphorylate the intracellular segments of the receptors, providing docking and phosphorylation sites for STAT6.

Dominant role of STAT6: Phosphorylated STAT6 forms homodimers, translocates to the nucleus, and directly binds to the promoter regions of numerous target genes, regulating the expression of GATA3, MHC class II molecules, FcεRII (CD23), and key enzymes involved in IgE class switching (e.g., AID). STAT6 is the executor of most of IL-4's biological functions.

IRS-PI3K pathway:

The intracellular region of the IL-4Rα chain contains docking sites for insulin receptor substrates (IRS). IL-4 stimulation phosphorylates IRS-1/2, thereby activating the PI3K-Akt pathway, primarily mediating metabolic, survival, and proliferative signals.

MAPK pathway:

This pathway is also mildly activated, participating in the regulation of cell proliferation and synergizing with the JAK-STAT and PI3K pathways.

IV. IL-4 and Related Diseases

IL-4-driven Th2 immune responses are a double-edged sword, with imbalances closely linked to various diseases.

1. Allergic Diseases

Allergic asthma and rhinitis: Inhaled allergens induce IL-4 production, driving Th2 responses, leading to specific IgE production, eosinophil infiltration, airway hyperresponsiveness, and excessive mucus secretion. Anti-IL-4Rα monoclonal antibodies (e.g., Dupilumab), which block both IL-4 and IL-13 signaling, have become breakthrough therapies for moderate-to-severe atopic dermatitis and asthma.

Atopic dermatitis: Skin barrier defects are associated with excessive IL-4/IL-13 production, resulting in chronic itching, inflammation, and structural changes in the skin.

2. Anti-Parasitic Infections

Helminth infections: IL-4 is a key protective factor in the body's resistance to gastrointestinal nematodes and other parasitic infections. It acts through inducing IgE, activating mast cells and eosinophils, and promoting M2 macrophage polarization to expel and kill parasites.

3. Fibrotic Diseases

Systemic sclerosis, pulmonary fibrosis, etc.: IL-4 (and IL-13) act through type II receptors on fibroblasts and epithelial cells, promoting collagen synthesis and extracellular matrix deposition, serving as important cytokines driving organ fibrosis.

4. Cancer

Dual roles: In the tumor microenvironment, IL-4 may have both pro-tumor and anti-tumor effects. On one hand, it can promote tumor growth, angiogenesis, and immune suppression by inducing M2-type tumor-associated macrophages (TAMs). On the other hand, in certain contexts, it can enhance anti-tumor antibody responses. IL-4R is overexpressed on some tumor cells (e.g., gliomas, renal cell carcinoma), making it a potential target for therapy.

5. Autoimmune Diseases

Multiple sclerosis, etc.: In contrast to Th1/Th17-driven diseases, IL-4 is generally considered protective, as its induced Th2 responses and M2 macrophages may help suppress excessive inflammatory damage.

V. Future Prospects: Therapeutic Potential of Targeting the IL-4 Pathway

In-depth understanding of the IL-4/IL-13 signaling pathway has led to revolutionary therapeutic strategies, with future directions including:

Expanded applications of biologics:

The success of Dupilumab: The remarkable success of anti-IL-4Rα monoclonal antibodies in allergic diseases has inspired the development and optimization of drugs targeting other nodes in this pathway (e.g., anti-IL-4, anti-IL-13 monoclonal antibodies) and expanded their indications to more Th2-related diseases (e.g., chronic rhinosinusitis with nasal polyps, eosinophilic esophagitis).

New strategies for cancer immunotherapy:

Overcoming immunosuppressive microenvironments: Developing drugs targeting IL-4R or blocking IL-4 signaling aims to reverse M2-type TAM polarization in the tumor microenvironment, relieve immune suppression, and potentially synergize with checkpoint inhibitors.

Antibody-drug conjugates: Leveraging IL-4R overexpression on tumor cells, IL-4 or anti-IL-4R antibodies can be used as carriers for targeted toxins or radiopharmaceuticals.

Breakthroughs in treating fibrotic diseases:

Blocking IL-4/IL-13 signaling is considered a highly promising direction for treating progressive fibrotic diseases (e.g., idiopathic pulmonary fibrosis), with related clinical trials underway.

Vaccine adjuvant development:

Using IL-4 as an adjuvant to bias toward Th2 responses and antibody production may be suitable for vaccine designs requiring robust humoral immune protection (e.g., certain parasitic vaccines or viral vaccines requiring neutralizing antibodies).

Conclusion

Interleukin-4 is one of the core regulatory factors in the immune system's "strategic decision-making," defining the establishment and maintenance of Th2-type immune responses. From driving B cells to produce IgE in allergies, to guiding macrophages in tissue repair, and assisting the body in fighting parasites, IL-4's functions profoundly influence the balance between immune defense, pathological damage, and tissue homeostasis. From its initial discovery as a B cell growth factor to today's receptor blockers serving as cornerstones in allergy treatment, research on IL-4 perfectly illustrates the path from basic immunological discovery to revolutionary therapies. In the future, more precise modulation of IL-4 signaling will continue to show broad application prospects in treating allergies, fibrosis, cancer, and infectious diseases.